



(12) Translation of
European patent specification

(11) NO/EP 2264009 B1

NORWAY

(19) NO

(51) Int Cl. *A61P 19/00 (2006.01)*
C07D 213/74 (2006.01) *A61P 43/00 (2006.01)*
A61K 31/4439 (2006.01) *C07D 401/14 (2006.01)*
A61K 31/444 (2006.01) *C07D 405/14 (2006.01)*
A61K 31/501 (2006.01) *C07D 409/14 (2006.01)*
A61K 31/506 (2006.01) *C07D 417/12 (2006.01)*
A61P 11/00 (2006.01) *C07D 417/14 (2006.01)*
A61P 11/06 (2006.01)

Norwegian Industrial Property Office

(21) Translation Published 2019.05.20

(80) Date of The European Patent Office Publication of the Granted Patent 2019.03.06

(86) European Application Nr. 09721163.5

(86) European Filing Date 2009.03.12

(87) The European Application's Publication Date 2010.12.22

(30) Priority 2008.03.12, JP, 2008062926

(84) Designated Contracting States: AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; TR

(73) Proprietor Ube Industries, Ltd., 1978-96, Oaza Kogushi, Ube-shi, Yamaguchi 755-8633, Japan

(72) Inventor IWAMURA, Ryo, c/o UBE INDUSTRIES, LTD.1978-96, Oaza KogushiUbe-shi, Yamaguchi 755-8633, Japan
TANAKA, Masayuki, c/o UBE INDUSTRIES, LTD.1978-96, Oaza KogushiUbe-shi, Yamaguchi 755-8633, Japan
KATSUBE, Tetsushi, c/o UBE INDUSTRIES, LTD.1978-96, Oaza KogushiUbe-shi, Yamaguchi 755-8633, Japan
SHIGETOMI, Manabu, c/o UBE INDUSTRIES, LTD.1978-96, Oaza KogushiUbe-shi, Yamaguchi 755-8633, Japan
OKANARI, Eiji, c/o UBE INDUSTRIES, LTD.1978-96, Oaza KogushiUbe-shi, Yamaguchi 755-8633, Japan
TOKUNAGA, Yasunori, c/o UBE INDUSTRIES, LTD.1978-96, Oaza KogushiUbe-shi, Yamaguchi 755-8633, Japan
FUJIWARA, Hiroshi, c/o UBE INDUSTRIES, LTD.1978-96, Oaza KogushiUbe-shi, Yamaguchi 755-8633, Japan

(74) Agent or Attorney BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge

(54) Title **PYRIDYLAMINOACETIC ACID COMPOUND**


(56) References

Cited: WO-A1-2004/078169
JP-T- 2008 505 874
WO-A2-2007/017687
WO-A2-2008/015517
WO-A1-2006/005909
WO-A1-99/19300
JP-T- 2005 521 668
WO-A1-03/016254
JP-T- 2006 519 250
JP-T- 2001 519 414

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Pyridylaminoeddiksyreforbindelse representert ved formel (1):



hvor

5 R¹ representerer et hydrogenatom, en metylgruppe, en etylgruppe, en isopropylgruppe eller en heksylgruppe,

R² og R³ representerer begge hydrogenatomer,

Y representerer en benzofuran-2-ylgruppe, en benzo[b]tiofen-2-ylgruppe, en 6-klorbenzo[b]tiofen-2-ylgruppe, en 6-metoksybenzo[b]tiofen-2-ylgruppe, en bifenyl-4-ylgruppe, en 4'-fluorbifenyl-4-ylgruppe, en 4'-klorbifenyl-4-ylgruppe, en 4-(pyrazol-1-yl)fenylgruppe, en 4-(tiazol-2-yl)fenylgruppe, en 4-(5-klortiazol-2-yl)fenylgruppe, en 4-(5-metyltiazol-2-yl)fenylgruppe, en 4-(4,5-dimetyltiazol-2-yl)fenylgruppe, en 4-(4-trifluormetyltiazol-2-yl)fenylgruppe, en 4-(tiazol-4-yl)fenylgruppe, en 4-(1,2,4-triazol-1-yl)fenylgruppe, en 4-(pyridin-2-yl)fenylgruppe, en 4-(pyridazin-4-yl)fenylgruppe, en 4-(pyrimidin-2-yl)fenylgruppe, en 4-(4,5-dihydrotiazol-2-yl)fenylgruppe eller en 6-fenylpyridazin-3-ylgruppe

og

Z representerer en fenylgruppe, en 2-fluorfenylgruppe, en 3-fluorfenylgruppe, en 4-fluorfenylgruppe, en 2-klorfenylgruppe, en 3-klorfenylgruppe, en 4-klorfenylgruppe, en 2,6-diklorfenylgruppe, en 4-metoksyfenylgruppe, en pyridin-2-ylgruppe eller en pyridin-3-ylgruppe,

eller et farmakologisk akseptabelt salt derav.

2. Pyridylaminoeddiksyreforbindelse eller farmakologisk akseptabelt salt derav ifølge krav 25 1, hvor pyridylaminoeddiksyreforbindelsen er:

{6-[(benzofuran-2-ylmetyl)(pyridin-3-ylsulfonyl)aminometyl]pyridin-2-ylamino}-eddiksyre,

{6-[(benzo[b]tiofen-2-ylmetyl)(pyridin-3-ylsulfonyl)aminometyl]pyridin-2-ylamino}eddiksyre,

{6-[(6-klorbenzo[b]tiofen-2-ylmetyl)(pyridin-3-ylsulfonyl)aminometyl]pyridin-2-ylamino}eddiksyre,

{6-[(6-metoksybenzo[b]tiofen-2-ylmetyl)(pyridin-3-ylsulfonyl)aminometyl]-pyridin-2-ylamino}eddiksyre,

5 {6-[(bifenyl-4-ylmetyl)(pyridin-2-ylsulfonyl)aminometyl]pyridin-2-ylamino}eddiksyre,

{6-[(bifenyl-4-ylmetyl)(pyridin-3-ylsulfonyl)aminometyl]pyridin-2-ylamino}eddiksyre,

{6-[(4'-fluorbifenyl-4-ylmetyl)(pyridin-3-ylsulfonyl)aminometyl]pyridin-2-ylamino}eddiksyre,

10 {6-[(4'-klorbifenyl-4-ylmetyl)(pyridin-3-ylsulfonyl)aminometyl]pyridin-2-ylamino}eddiksyre,

(6-{(4-fluorbenzensulfonyl)[4-(pyrazol-1-yl)benzyl]aminometyl}pyridin-2-ylamino)eddiksyre,

(6-{[4-(pyrazol-1-yl)benzyl](pyridin-2-ylsulfonyl)aminometyl}pyridin-2-ylamino)-eddiksyre,

15 (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminometyl}pyridin-2-ylamino)-eddiksyre,

isopropyl(6-{(pyridin-2-ylsulfonyl)[4-(tiazol-2-yl)benzyl]aminometyl}pyridin-2-ylamino)acetat,

20 etyl(6-{(pyridin-2-ylsulfonyl)[4-(tiazol-2-yl)benzyl]aminometyl}pyridin-2-ylamino)acetat,

(6-{(4-fluorbenzensulfonyl)[4-(tiazol-2-yl)benzyl]aminometyl}pyridin-2-ylamino)-eddiksyre,

(6-{(pyridin-2-ylsulfonyl)[4-(tiazol-2-yl)benzyl]aminometyl}pyridin-2-ylamino)-eddiksyre,

25 (6-{(pyridin-3-ylsulfonyl)[4-(tiazol-2-yl)benzyl]aminometyl}pyridin-2-ylamino)-eddiksyre,

(6-{{(pyridin-2-ylsulfonyl)[4-(4-trifluormetyltiazol-2-yl)benzyl]aminometyl}}-pyridin-2-ylamino)eddiksyre,

(6-{{(pyridin-2-ylsulfonyl)[4-(tiazol-4-yl)benzyl]aminometyl}}pyridin-2-ylamino)-eddiksyre,

5 (6-{{[4-(pyridin-2-yl)benzyl](pyridin-3-ylsulfonyl)aminometyl}}pyridin-2-ylamino)-eddiksyre,

(6-{{[4-(pyridazin-4-yl)benzyl](pyridin-3-ylsulfonyl)aminometyl}}pyridin-2-ylamino)-eddiksyre,

10 (6-{{(pyridin-2-ylsulfonyl)[4-(pyrimidin-2-yl)benzyl]aminometyl}}pyridin-2-ylamino)-eddiksyre,

(6-{{[4-(4,5-dihydrotiazol-2-yl)benzyl](4-fluorbensensulfonyl)aminometyl}}pyridin-2-ylamino)eddiksyre,

{6-{{(6-fenylpyridazin-3-ylmetyl)(pyridin-3-ylsulfonyl)aminometyl}}pyridin-2-yl-amino}eddiksyre,

15 heksyl(6-{{(pyridin-2-ylsulfonyl)[4-(tiazol-2-yl)benzyl]aminometyl}}pyridin-2-yl-amino)acetat,

(6-{{[4-(5-klortiazol-2-yl)benzyl](pyridin-2-ylsulfonyl)aminometyl}}pyridin-2-yl-amino)eddiksyre,

20 (6-{{[4-(5-metyltiazol-2-yl)benzyl](pyridin-2-ylsulfonyl)aminometyl}}pyridin-2-yl-amino)eddiksyre,

(6-{{[4-(4,5-dimetyltiazol-2-yl)benzyl](pyridin-2-ylsulfonyl)aminometyl}}pyridin-2-ylamino)eddiksyre,

(6-{{(pyridin-3-ylsulfonyl)[4-(1,2,4-triazol-1-yl)benzyl]aminometyl}}pyridin-2-yl-amino)eddiksyre,

25 etyl(6-{{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminometyl}}pyridin-2-yl-amino)acetat, eller

isopropyl(6-{{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminometyl}}pyridin-2-ylamino)acetat.

3. Farmasøytisk preparat omfattende pyridylaminoeddiksyreforbindelse ifølge krav 1 eller 2 eller et farmakologisk akseptabelt salt derav som en aktiv bestanddel.
4. Farmasøytiske preparatet ifølge krav 3 for forhindring eller behandling av en
- 5 respiratorisk sykdom.